Trials / Completed
CompletedNCT02451930
A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
An Open-Label, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of the Combination of Necitumumab With Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizumab in participants with stage IV non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Necitumumab | Administered IV |
| DRUG | Pembrolizumab | Administered IV |
Timeline
- Start date
- 2015-09-04
- Primary completion
- 2017-01-26
- Completion
- 2019-09-17
- First posted
- 2015-05-22
- Last updated
- 2020-10-05
- Results posted
- 2020-10-05
Locations
16 sites across 4 countries: United States, France, Japan, Spain
Source: ClinicalTrials.gov record NCT02451930. Inclusion in this directory is not an endorsement.